Altered Levels of Sphingosine, Sphinganine and Their Ceramides in Atopic Dermatitis Are Related to Skin Barrier Function, Disease Severity and Local Cytokine Milieu.
atopic dermatitis
biomarkers
ceramides
sphinganine
sphingosine
stratum corneum
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
13 Mar 2020
13 Mar 2020
Historique:
received:
19
02
2020
revised:
07
03
2020
accepted:
09
03
2020
entrez:
19
3
2020
pubmed:
19
3
2020
medline:
2
12
2020
Statut:
epublish
Résumé
Dysfunctional skin barrier plays a key role in the pathophysiology of atopic dermatitis (AD), a common inflammatory skin disease. Altered composition of ceramides is regarded as a major cause of skin barrier dysfunction, however it is not clear whether these changes are intrinsic or initiated by inflammation and aberrant immune response in AD. This study investigated the levels of free sphingoid bases (SBs) sphingosine and sphinganine and their ceramides and glucosylceramide in the stratum corneum (SC) and related them to skin barrier function, disease severity and local cytokine milieu. Ceramides were measured in healthy skin, and lesional and non-lesional skin of AD patients by a novel method based on deacylation of ceramides which were subsequently determined as corresponding sphingoid bases by using liquid chromatography-tandem mass spectrometry (LC-MS/MS). The cytokine levels were determined by multiplex immunoassay. Atopic skin showed increased levels of most investigated markers, predominantly in lesional skin. The largest difference in respect to healthy skin was found for glucosylceramide with respective median values of 0.23 (IQR 0.18-0.61), 0.56 (IQR 0.32-0.76) and 19.32 (IQR 7.86-27.62) pmol/g protein for healthy, non-lesional and lesional skin. The levels of investigated ceramide markers were correlated with disease severity (scoring atopic dermatitis, SCORAD) and skin barrier function (trans-epidermal water loss, TEWL) and furthermore with cytokines involved in innate, Th-1, and Th-2 immune response. Interestingly, the strongest association with SCORAD was found for sphinganine/sphingosine ratio (
Identifiants
pubmed: 32183011
pii: ijms21061958
doi: 10.3390/ijms21061958
pmc: PMC7139865
pii:
doi:
Substances chimiques
Biomarkers
0
Ceramides
0
Cytokines
0
Sphingosine
NGZ37HRE42
safingol
OWA98U788S
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
J Invest Dermatol. 2010 Oct;130(10):2511-4
pubmed: 20574438
Biochim Biophys Acta. 2014 Mar;1841(3):295-313
pubmed: 24252189
Anal Bioanal Chem. 2016 Sep;408(24):6623-36
pubmed: 27473427
Biochim Biophys Acta. 2014 Mar;1841(3):422-34
pubmed: 23988654
Clin Chem. 2007 Apr;53(4):742-7
pubmed: 17332150
J Dermatol Sci. 2020 Jan;97(1):2-8
pubmed: 31866207
Curr Allergy Asthma Rep. 2009 Jul;9(4):265-72
pubmed: 19656472
J Invest Dermatol. 1991 Apr;96(4):523-6
pubmed: 2007790
J Invest Dermatol. 1983 Jun;80(1 Suppl):44s-9s
pubmed: 20479733
JCI Insight. 2018 Feb 22;3(4):
pubmed: 29467325
Cytokine. 2010 May;50(2):181-5
pubmed: 20236835
Biochim Biophys Acta. 2014 Jan;1841(1):70-9
pubmed: 24120918
Biochim Biophys Acta. 2016 Nov;1861(11):1652-1661
pubmed: 27422369
J Dermatol Sci. 2017 Oct;88(1):57-66
pubmed: 28571749
Adv Exp Med Biol. 1997;407:421-31
pubmed: 9321986
Clin Chem. 2013 Mar;59(3):547-56
pubmed: 23237761
J Lipid Res. 2008 Jul;49(7):1466-76
pubmed: 18359959
Pediatr Allergy Immunol. 2016 Feb;27(1):99-102
pubmed: 26388323
J Clin Invest. 2009 Jan;119(1):47-60
pubmed: 19075398
Ann Allergy Asthma Immunol. 2018 Jan;120(1):34-41
pubmed: 29126710
Biochimie. 2017 Oct;141:91-96
pubmed: 28341550
Skin Pharmacol Physiol. 2013;26(1):36-44
pubmed: 23128426
J Allergy Clin Immunol. 2018 Jun;141(6):2094-2106
pubmed: 29731129
J Allergy Clin Immunol. 2008 Jun;121(6):1337-43
pubmed: 18329087
J Am Acad Dermatol. 2014 Jul;71(1):177-84
pubmed: 24656726
J Lipid Res. 2011 Jun;52(6):1211-21
pubmed: 21444759
J Allergy Clin Immunol. 2009 Dec;124(6):1235-1244.e58
pubmed: 20004782
J Lipid Res. 2012 Dec;53(12):2755-66
pubmed: 23024286
J Allergy Clin Immunol. 2019 Jan;143(1):155-172
pubmed: 30194992
Br J Dermatol. 2019 Mar;180(3):586-596
pubmed: 30132823
Metabolomics. 2018 May 9;14(5):69
pubmed: 30830395
J Am Acad Dermatol. 2019 Aug;81(2):510-519
pubmed: 31009665
J Allergy Clin Immunol. 2019 Jan;143(1):26-35
pubmed: 30476499
J Immunol Res. 2019 Jan 29;2019:3030268
pubmed: 30838224
Dermatology. 1997;195(1):10-9
pubmed: 9267730
Ann Allergy Asthma Immunol. 2017 Nov;119(5):446-451
pubmed: 28866311
Curr Allergy Asthma Rep. 2008 Jul;8(4):299-305
pubmed: 18606081
Exp Dermatol. 2014 Jan;23(1):45-52
pubmed: 24299153
J Dermatol Sci. 2013 Dec;72(3):296-303
pubmed: 24070864
J Invest Dermatol. 2014 Mar;134(3):712-718
pubmed: 24008422
J Invest Dermatol. 2002 Aug;119(2):433-9
pubmed: 12190867
Skin Res Technol. 2019 Jan;25(1):3-11
pubmed: 30030941
Dermatitis. 2018 Jul/Aug;29(4):219-222
pubmed: 29939855
Crit Care. 2002 Aug;6(4):335-41
pubmed: 12225610
J Invest Dermatol. 2014 Jul;134(7):1941-1950
pubmed: 24518171
Curr Probl Dermatol. 2016;49:8-26
pubmed: 26844894
J Dermatol Sci. 2012 Oct;68(1):25-35
pubmed: 22884781
Prog Lipid Res. 2016 Jul;63:50-69
pubmed: 27107674
Nat Rev Dis Primers. 2018 Jun 21;4(1):1
pubmed: 29930242